BRPI0921019A2 - processo para obtenção de uma composição de rosuvastatina cálcica e produto obtido - Google Patents

processo para obtenção de uma composição de rosuvastatina cálcica e produto obtido

Info

Publication number
BRPI0921019A2
BRPI0921019A2 BRPI0921019A BRPI0921019A BRPI0921019A2 BR PI0921019 A2 BRPI0921019 A2 BR PI0921019A2 BR PI0921019 A BRPI0921019 A BR PI0921019A BR PI0921019 A BRPI0921019 A BR PI0921019A BR PI0921019 A2 BRPI0921019 A2 BR PI0921019A2
Authority
BR
Brazil
Prior art keywords
obtaining
composition
product obtained
calcium rosuvastatin
rosuvastatin
Prior art date
Application number
BRPI0921019A
Other languages
English (en)
Inventor
Kenia Lizeth Maya Ayala
Luis Estrada Flores
Original Assignee
Psicofarma S A De C V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Psicofarma S A De C V filed Critical Psicofarma S A De C V
Publication of BRPI0921019A2 publication Critical patent/BRPI0921019A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BRPI0921019A 2008-11-10 2009-07-29 processo para obtenção de uma composição de rosuvastatina cálcica e produto obtido BRPI0921019A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
MX2008014321A MX344885B (es) 2008-11-10 2008-11-10 Proceso para la obtencion de una composicion de rosuvastatina calcica y producto obtenido.
PCT/MX2009/000081 WO2010053343A1 (es) 2008-11-10 2009-07-29 Proceso para la obtención de una composición de rosuvastatina cálcica y producto obtenido

Publications (1)

Publication Number Publication Date
BRPI0921019A2 true BRPI0921019A2 (pt) 2015-12-22

Family

ID=42153048

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0921019A BRPI0921019A2 (pt) 2008-11-10 2009-07-29 processo para obtenção de uma composição de rosuvastatina cálcica e produto obtido

Country Status (8)

Country Link
US (1) US20120269890A1 (pt)
EP (1) EP2347758A4 (pt)
JP (1) JP2012508230A (pt)
BR (1) BRPI0921019A2 (pt)
CA (1) CA2744820C (pt)
MX (1) MX344885B (pt)
NZ (1) NZ593349A (pt)
WO (1) WO2010053343A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200003219A (ko) 2011-05-20 2020-01-08 아스트라제네카 유케이 리미티드 로수바스타틴 칼슘의 약학 조성물
CN103874490A (zh) * 2011-08-15 2014-06-18 工业研究与发展基金会有限公司 咔咯和他汀类药物的组合
JP6161867B2 (ja) * 2011-11-17 2017-07-12 株式会社アドバンテスト 滑沢剤の展延解析装置、方法、プログラム、記録媒体
WO2013083674A1 (de) * 2011-12-08 2013-06-13 Hexal Ag Neue pharmazeutische statin-zusammensetzung
JP2016098187A (ja) * 2014-11-19 2016-05-30 ニプロ株式会社 口腔内崩壊錠
JP6108635B2 (ja) * 2015-05-14 2017-04-05 ダイト株式会社 ロスバスタチン含有口腔内速崩壊錠
JP6167192B2 (ja) * 2016-01-19 2017-07-19 株式会社アドバンテスト 滑沢剤の展延解析装置、方法、プログラム、記録媒体
CN110151725B (zh) * 2019-06-26 2021-06-18 海南通用三洋药业有限公司 一种稳定的瑞舒伐他汀钙胶囊剂及其制备方法
CN110974793A (zh) * 2019-12-26 2020-04-10 鲁南制药集团股份有限公司 一种瑞舒伐他汀钙片剂及其制备方法
CN113230223B (zh) * 2021-05-13 2023-04-07 宜昌人福药业有限责任公司 阿托伐他汀钙薄膜包衣片的制备方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8679534B2 (en) * 1997-12-12 2014-03-25 Andrx Labs, Llc HMG-CoA reductase inhibitor extended release formulation
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
GB0001621D0 (en) * 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
AR030414A1 (es) * 2000-04-03 2003-08-20 Astrazeneca Ab Combinacion farmaceutica que comprende un beta bloqueante y un inhibidor de hmg-coa reductasa , formulacion farmaceutica, equipo transportable de partes , uso de esta combinacion y de esta formulacion para preparar medicamentos
GB0111077D0 (en) * 2001-05-04 2001-06-27 Biochemie Gmbh Organic compounds
DE10204336A1 (de) * 2002-02-01 2003-08-14 Merck Patent Gmbh Verwendung von Mehrschichtpigmenten im Lebensmittel- und Pharmabereich
US20030171407A1 (en) * 2002-03-07 2003-09-11 Upsher-Smith Laboratories, Inc. Composition for reducing blood glucose and cholesterol
AU2003227691B2 (en) * 2002-05-03 2008-05-15 Hexal Ag Stable pharmaceutical formulation for a combination of a statin and an ace inhibitor
GB0217306D0 (en) * 2002-07-25 2002-09-04 Novartis Ag Compositions comprising organic compounds
AR040588A1 (es) * 2002-07-26 2005-04-13 Schering Corp Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
EP1599192A4 (en) * 2003-02-20 2009-06-03 Bpsi Holdings Inc SHIMMERING FILM COATING SYSTEMS AND SUBSTRATES THAT ARE COATED
US7179916B2 (en) * 2004-07-13 2007-02-20 Teva Pharmaceutical Industries Ltd. Process for the preparation of rosuvastatin
WO2006134604A1 (en) * 2005-06-15 2006-12-21 Hetero Drugs Limited Combination composition of cholesterol absorption inhibitor and 3-hydroxy-3-methylglutaryl-coenzyme a (hmg-coa) reductase inhibitor
EP1741427A1 (en) * 2005-07-06 2007-01-10 KRKA, D.D., Novo Mesto Pharmaceutical composition comprising simvastatin and ezetimibe
US20070053892A1 (en) * 2005-09-07 2007-03-08 Everett Laboratories, Inc. Methods and kits for co-administration of nutritional supplements
TW200744583A (en) * 2006-03-14 2007-12-16 Ranbaxy Lab Ltd Statin stabilizing dosage formulations
WO2008062476A2 (en) * 2006-10-31 2008-05-29 Glenmark Pharmaceutical Limited Pharmaceutical composition comprising rosuvastatin or pharmaceutically accepatble salts thereof
JP2010519216A (ja) * 2007-02-15 2010-06-03 ファイザー・リミテッド Ｃｃｒ５拮抗薬のための医薬組成物および方法
CL2008003154A1 (es) * 2007-10-26 2009-10-23 Eurofarma Laboratorios LTDA Proceso de obtencion de un extracto estandarizado de aleuterites moluccana; extracto estandarizado de aleurites moluccana; composicion farmaceutica que comprende el extracto; uso del extracto para tratar condiciones de dolor.

Also Published As

Publication number Publication date
WO2010053343A1 (es) 2010-05-14
CA2744820A1 (en) 2010-05-14
EP2347758A4 (en) 2012-04-25
NZ593349A (en) 2012-12-21
MX344885B (es) 2017-01-10
US20120269890A1 (en) 2012-10-25
MX2008014321A (es) 2010-06-07
CA2744820C (en) 2016-03-01
JP2012508230A (ja) 2012-04-05
EP2347758A1 (en) 2011-07-27

Similar Documents

Publication Publication Date Title
BRPI0921019A2 (pt) processo para obtenção de uma composição de rosuvastatina cálcica e produto obtido
BRPI0918153A2 (pt) peça de material e processo útil para a preparação de uma peça de material
BR112012031033A2 (pt) composição de si--g-poliolefina e processo para fazer uma composição de si-g-poliolefina
BRPI0905717A2 (pt) Composição farmacêutica, processo para preparar uma composição farmacêutica e forma de dosagem farmacêutica
BRPI0919192A2 (pt) Uso de lipídio, composição nutricional, e, processo para a produção de uma composição nutricional
BR112012000421A2 (pt) composições e métodos para intensificar a produção de um produto biológico.
BRPI0905080A2 (pt) Composições, processo para reparar uma composição e produto
BRPI0721502A2 (pt) Método para tratamento de uma formação fraturada
BRPI0814997A2 (pt) Métodos térmicos para tratamento de uma matéria-prima de metátese
BRPI0915205A2 (pt) compostos e composições úteis para o tratamento de malária
BRPI0916712A2 (pt) processo para preparar uma composição detergente
BRPI0921718A2 (pt) composição, método para produzir uma composição, e, artigo moldado
BRPI0910454A2 (pt) processo para produção de uma proteína policlonal
BRPI1007833A2 (pt) processo para produzir uma manta gofrada
BRPI1008127A2 (pt) "composição e processo para a preparação de uma espuma termoplástica ou termofixa"
BRPI0917751A2 (pt) parafuso ósseo
BRPI0819946A2 (pt) Composição de matéria e método para preparar uma composição tensoativa
BR112012015100A2 (pt) composição de polímero modificado, artigo e método para produzir uma composição de polímero modificado
FI20070569A0 (fi) Uusi stabiili tuote ja menetelmä sen valmistamiseksi
BRPI0921399A2 (pt) composição de graxa lubrificante, processo para preparar composição lubrificante, e, uso de uma composição de graxa lubrificante
BRPI0910545A2 (pt) processo contínuo para fazer composições farmacêuticas
BRPI0915572A2 (pt) processo para a fabricação de epicloroidrina
BR112012008850A2 (pt) processo para produção de materiais poliméricos biodegradáveis
FI20085767A0 (fi) Kipsituote
BRPI0916512A2 (pt) processo para produzir uma composição agroquímica de partícula dispersível em água

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2383 DE 06-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.